Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Courtney H. Bouk"'
Autor:
Chih Jian Lih, P. Mickey Williams, Jonathan C. Yau, Vivekananda Datta, Keyur P. Patel, Eric C. Polley, Kneshay N. Harper, James H. Doroshow, Long P. Le, Jeffrey Sklar, Savitri Krishnamurthy, Amelia Raymond, Rajesh R. Singh, Zenta Walther, Karin E. Finberg, Sandra Canosa, Rajyalakshmi Luthra, Karyn Ronski, Hayley Robinson, A. John Iafrate, Stanley R. Hamilton, David J. Sims, Geeta S. Mantha, Lisa M. McShane, Mark J. Routbort, Barbara A. Conley, Courtney H. Bouk, Robin D. Harrington
Publikováno v:
The Journal of Molecular Diagnostics. 19:313-327
The National Cancer Institute–Molecular Analysis for Therapy Choice (NCI-MATCH) trial is a national signal-finding precision medicine study that relies on genomic assays to screen and enroll patients with relapsed or refractory cancer after standar
Autor:
Paul M. Williams, James H. Doroshow, Robin D. Harrington, Larry Rubinstein, Yingdong Zhao, William D. Walsh, Michele G. Mehaffey, David J. Sims, Barbara A. Conley, Thomas Forbes, Courtney H. Bouk, Vivekananda Datta, Biswajit Das, Alice P. Chen, Richard M. Simon, Shivaani Kummar, Kneshay N. Harper, Chih Jian Lih, Eric C. Polley
Publikováno v:
The Journal of Molecular Diagnostics. 18:51-67
Robust and analytically validated assays are essential for clinical studies. We outline an analytical validation study of a targeted next-generation sequencing mutation-detection assay used for patient selection in the National Cancer Institute Molec
Autor:
Jason D. Peterson, Robin D. Harrington, Lorn Davis, Bharathi Anekella, Andrea Ferreira-Gonzalez, Gregory J. Tsongalis, Vishal Kumar Sarsani, Helen Fernandes, Stephen Haralampu, Yves Konigshofer, Catherine Huang, Catherine I. Dumur, Vanessa Spotlow, Francine B. de Abreu, Robert Daber, Russell K. Garlick, Courtney H. Bouk, Chih-Jian Lih, P. Mickey Williams, Sophie J. Deharvengt
Publikováno v:
The journal of applied laboratory medicine. 2(2)
Background Next-generation sequencing (NGS) assays are highly complex tests that can vary substantially in both their design and intended application. Despite their innumerous advantages, NGS assays present some unique challenges associated with the
Autor:
Chih-Jian, Lih, Robin D, Harrington, David J, Sims, Kneshay N, Harper, Courtney H, Bouk, Vivekananda, Datta, Jonathan, Yau, Rajesh R, Singh, Mark J, Routbort, Rajyalakshmi, Luthra, Keyur P, Patel, Geeta S, Mantha, Savitri, Krishnamurthy, Karyn, Ronski, Zenta, Walther, Karin E, Finberg, Sandra, Canosa, Hayley, Robinson, Amelia, Raymond, Long P, Le, Lisa M, McShane, Eric C, Polley, Barbara A, Conley, James H, Doroshow, A John, Iafrate, Jeffrey L, Sklar, Stanley R, Hamilton, P Mickey, Williams
Publikováno v:
The Journal of molecular diagnostics : JMD. 19(2)
The National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH) trial is a national signal-finding precision medicine study that relies on genomic assays to screen and enroll patients with relapsed or refractory cancer after standard
Autor:
David J. Sims, Corinne Camalier, P. Mickey Williams, Kneshay N. Harper, Barbara A. Conley, James H. Doroshow, Paul M. McGregor, Biswajit Das, Courtney H. Bouk, Robin D. Harrington, Thomas Forbes, Chih Jian Lih, Eric C. Polley, Michele G. Mehaffey
Although next-generation sequencing technologies have been widely adapted for clinical diagnostic applications, an urgent need exists for multianalyte calibrator materials and controls to evaluate the performance of these assays. Control materials wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0e8fc30838f960e73cd330347249022
https://europepmc.org/articles/PMC4851732/
https://europepmc.org/articles/PMC4851732/